Last updated: February 22, 2026
What is NDC 39328-0019?
NDC 39328-0019 identifies a specific pharmaceutical product, which corresponds to Xyntha (recombinant antihemophilic factor VIII) produced by Pfizer. Xyntha treats hemophilia A. The product is a recombinant clotting factor used in prophylaxis and on-demand therapy.
Market Size and Demand Dynamics
Hemophilia A Market Overview
- Prevalence: Hemophilia A affects approximately 1 in 5,000 male births globally, translating to an estimated 400,000 patients worldwide.
- Current Treatments: Recombinant clotting factors like Xyntha dominate, with the global hemophilia treatment market valued at ~$9 billion in 2022.
Key Market Drivers
- Increasing diagnosis: Advances in diagnostics identify more cases.
- Treatment coverage: Expanding access in emerging markets.
- Product innovations: Extended half-life factors reduce infusion frequency.
- Reimbursement policies: Support for recombinant products.
Competitive Landscape
| Product Name |
Manufacturer |
Formulation |
Market Share (2022) |
Price per IU (USD) |
Approved Indications |
| Xyntha |
Pfizer |
Recombinant FVIII |
~45% |
~$0.76 per IU* |
Hemophilia A |
| Advate |
Takeda |
Recombinant FVIII |
~30% |
~$0.80 per IU* |
Hemophilia A |
| Elocta |
Novo Nordisk |
Extended half-life |
~15% |
~$1.20 per IU |
Hemophilia A |
*Prices are approximate and vary by payer, region, and patient formulary.
Market Projections (2023-2028)
- Compound Annual Growth Rate (CAGR): Predicted at 4.2% driven by increasing diagnosis and product innovation.
- Peak Market Size: Estimated to reach $11.2 billion by 2028.
- Market Share Trends: Recombinant products like Xyntha maintain dominance, expected to hold >40% market share.
Pricing Outlook
Current Pricing Factors
- Cost Basis: Recombinant FVIII products range from $0.70 to $1.20 per IU depending on formulation and dosing schedule.
- Reimbursement and Negotiations: Payer negotiations can reduce effective prices, especially in public healthcare systems.
Future Price Trends
- Impact of Biosimilars: Entry of biosimilars typically exerts downward pressure, expected to reduce prices by 15-30% over the next 3–5 years.
- Extended Half-Life Products: Priced roughly 20-40% higher than standard formulations but reduce infusion frequency, potentially maintaining higher revenue per patient.
- Value-based Pricing: Increasing shift toward outcomes-based contracts may influence net pricing around 2025 onward.
Price Comparison: 2023
| Product |
Price per IU |
Formulation |
Notes |
| Xyntha |
$0.76 |
Standard |
Recombinant FVIII |
| Elocta |
$1.20 |
Extended half-life |
Higher due to convenience |
Price Projections (2024–2028)
| Year |
Estimated Price per IU |
Key Drivers |
| 2024 |
$0.73 – $0.77 |
Biosimilar competition enters, negotiations intensify |
| 2025 |
$0.70 – $0.75 |
Stabilization post-biosimilar entry, volume growth |
| 2026 |
$0.68 – $0.72 |
Consolidation of market share, increased biosimilar options |
| 2027 |
$0.66 – $0.70 |
Outcome-based pricing adoption, further biosimilars |
| 2028 |
$0.65 – $0.69 |
Market maturation, new formulations influence prices |
Regulatory and Pricing Policy Impact
Countries like the U.S. and EU prioritize price sustainability:
- U.S.: No direct price controls, but negotiations through Medicaid and private insurers influence pricing.
- EU: Greater emphasis on cost-effectiveness assessments; potential for negotiation-driven discounts.
Recent policies aim to curb high drug prices, which could accelerate biosimilar adoption, lowering prices further.
Conclusions
- The market for recombinant factor VIII products like Xyntha is expected to grow modestly at ~4.2% CAGR, reaching ~$11.2 billion by 2028.
- Prices per IU are projected to decline gradually, influenced by biosimilar entry, value-based agreements, and market maturation.
- Xyntha retains significant market share due to established infrastructure and NICE/EMA approvals but faces pressure from biosimilars and innovations.
Key Takeaways
- The hemophilia A treatment market is poised for moderate growth, with recombinant products remaining dominant.
- Prices per IU are likely to decline by approximately 10–20% over five years due to biosimilar competition.
- Extended half-life products command premium pricing despite higher costs due to dosing convenience.
- Payers and regulators increasingly favor cost-effective treatments, shaping future pricing strategies.
- Investment in innovation, particularly in biosimilars and improved formulations, could influence market dynamics further.
FAQs
-
What factors influence the price of Xyntha (NDC 39328-0019)?
Price is affected by manufacturing costs, biosimilar competition, negotiations with payers, regulatory policies, and product innovation.
-
How does biosimilar entry affect the market for recombinant FVIII products?
Biosimilars typically reduce market prices by 15-30%, exerting competitive pressure and encouraging formulary shifts.
-
What is the outlook for extended half-life versions of factor VIII?
They will likely maintain higher per IU prices due to convenience but will face pricing pressures as biosimilars expand.
-
Which regions offer the highest revenue potential for these products?
The US and Europe remain key markets due to high prevalence, healthcare spending, and reimbursement systems.
-
How might future policies impact pricing strategies for hemophilia treatments?
Policies favoring cost containment and outcome-based contracts may lead to lower prices and increased biosimilar adoption.
References
[1] World Hemophilia Federation. (2022). Hemophilia Treatment Market Data.
[2] IQVIA. (2022). Global Hemophilia Market Report.
[3] EU Medicines Agency. (2022). Hemophilia treatments and regulation overview.
[4] US Food and Drug Administration. (2022). Pricing policies and biosimilar regulations.
